Pain Therapeutics Resubmits New Drug Application for Remoxy ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain

AUSTIN, Texas, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today the resubmission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for Remoxy ER, its lead drug candidate. The...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news